Reply to: Correspondence on 'Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network'
J Hepatol. 2024 Dec 17:S0168-8278(24)02775-2.
doi: 10.1016/j.jhep.2024.12.020.
Online ahead of print.
1 Department of Pharmacology and Pediatrics, Servicio de Farmacologia Clinica, University Hospital Virgen de la Victoria, IBIMA_Plataforma Bionand, University of Malaga, Malaga, Spain; Centro de Investigación Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd) Madrid, Spain.
2 Department of Pharmacology and Pediatrics, Servicio de Farmacologia Clinica, University Hospital Virgen de la Victoria, IBIMA_Plataforma Bionand, University of Malaga, Malaga, Spain; Centro de Investigación Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd) Madrid, Spain. Electronic address: [email protected].
3 Centro de Investigación Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd) Madrid, Spain; Department of Medicine, Servicio de Digestivo, University Hospital Virgen de la Victoria IBIMA_Plataforma Bionand, University of Malaga, Malaga, Spain.